168 related articles for article (PubMed ID: 9543456)
1. Longitudinal comparison of HIV-1 RNA burden in plasma and cerebrospinal fluid in two patients starting triple combination antiretroviral therapy.
Iftimovici E; Rabian C; Burgard M; Peytavin G; Rouzioux C; Viard JP
AIDS; 1998 Mar; 12(5):535-7. PubMed ID: 9543456
[No Abstract] [Full Text] [Related]
2. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
[TBL] [Abstract][Full Text] [Related]
4. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
5. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.
Stellbrink HJ; Eggers C; van Lunzen J; Albrecht H; Greten H
AIDS; 1997 Nov; 11(13):1655-7. PubMed ID: 9365775
[No Abstract] [Full Text] [Related]
6. Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system.
Delforge ML; Farber CM; De Leener F; Caroyer JM; Liesnard C; Van Vooren JP
Clin Infect Dis; 1999 Apr; 28(4):931. PubMed ID: 10825078
[No Abstract] [Full Text] [Related]
7. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
8. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
9. HIV encephalitis in a patient on antiretroviral therapy: a case report.
Hlebowicz M; Parczewski M; Jakubowski P
Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy.
Medeiros RP; Munerato P; Diaz RS
J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426
[No Abstract] [Full Text] [Related]
11. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma.
Monteiro de Almeida S; Letendre S; Zimmerman J; Lazzaretto D; McCutchan A; Ellis R
J Neuroimmunol; 2005 Dec; 169(1-2):144-52. PubMed ID: 16182380
[TBL] [Abstract][Full Text] [Related]
14. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
15. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
Bogoch II; Davis BT; Venna N
J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
[TBL] [Abstract][Full Text] [Related]
17. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
18. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
19. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
Valle M; Price RW; Nilsson A; Heyes M; Verotta D
Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955
[TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
